United States Breast Cancer Therapy Market Opportunity Analysis

Jul 15, 2015, 11:24 ET from Research and Markets

DUBLIN, July 10, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer) has announced the addition of the "US Breast Cancer Therapy Market Opportunity Analysis" report to their offering.

US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). The inhibition of HER2 is its basic mechanism to prevent the growth and proliferation of breast cancer in women. It was approved in 2012 by the FDA for the treatment of or late-stage metastatic HER2-positive breast cancer patients.

Various pharmaceutical companies are expected to introduce novel breast cancer medicines and technologies in future. Most of them are at different stages of clinical trials and would be introduced in coming years. However, the cost of pharmacologically superior therapeutics is quite high due to which limited breast cancer patients include them in their therapeutic regime. In future, the high cost breast cancer medicines will be replaced by affordable medicines due to advancements in technologies. Nanotechnology based breast cancer medicines are being developed whose introduction in US may take time. New molecular targets are also being investigated that would help in development of innovative medicines in coming years. These developments shows that US breast cancer market will increase as new products would be introduced. In this way, future of breast cancer therapeutics in US seems to be optimistic.

"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:

- US Breast Cancer Incidence & Prevalence
- US Breast Cancer Therapy Market Overview
- US Breast Cancer Drug Clinical Pipeline by Company & Phase
- US Breast Cancer Drug Clinical Pipeline: 251 Drugs
- Majority Drugs in Phase-II Trials: 73 Drugs
- Marketed Breast Cancer Drugs in US: 32 Drugs
- Breast Cancer Drug Patent Analysis

Key Topics Covered:

1. US Breast Cancer Incidence & Prevalence

2. US Breast Cancer Therapy Market Overview

3. US Breast Cancer Therapy Market Dynamics

4. US Breast Cancer Therapy Market Future Prospects

5. Mechanism of Breast Cancer Drugs

6. US Breast Cancer Drug Clinical Pipeline by Company & Phase

7. Marketed Breast Cancer Drug Clinical Insight & Patent Analysis by Company in US

8. Discontinued & Suspended Breast Cancer Drug in Clinical Pipeline in US

9. Competitive Landscape

- ARIAD Pharmaceuticals
- AbbVie
- Agilent Technologies
- AstraZeneca
- Bayer
- BioMarin Pharmaceutical
- Biodesix
- Boehringer Ingelheim
- Bristol Mayer
- Celgene Corporation
- Dako A/S
- Debiopharm
- Dyax
- Eisai
- Eli Lily
- Exelixis
- GalaxoSmithKline
- Incyte Corporation
- Ligand Pharmaceuticals
- Merck
- Navidea Biopharmaceuticals
- Nektar Therapeutics
- Novartis
- Onyx pharmaceuticals
- Pfizer
- Roche
- Sanofi
- Squibb
- Sun Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com